| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacoepidemiology | 51 | 2024 | 351 | 7.050 |
Why?
|
| Comparative Effectiveness Research | 32 | 2023 | 713 | 6.400 |
Why?
|
| Propensity Score | 65 | 2024 | 1962 | 5.890 |
Why?
|
| Product Surveillance, Postmarketing | 24 | 2019 | 465 | 5.370 |
Why?
|
| Databases, Factual | 85 | 2024 | 8075 | 5.340 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 17 | 2024 | 317 | 3.400 |
Why?
|
| Research Design | 43 | 2024 | 6210 | 3.350 |
Why?
|
| Randomized Controlled Trials as Topic | 35 | 2024 | 10377 | 3.200 |
Why?
|
| Warfarin | 20 | 2023 | 1493 | 3.180 |
Why?
|
| Anticoagulants | 31 | 2024 | 4843 | 3.180 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 22 | 2017 | 321 | 3.000 |
Why?
|
| Electronic Health Records | 39 | 2024 | 4875 | 2.890 |
Why?
|
| Insurance, Pharmaceutical Services | 21 | 2013 | 348 | 2.830 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 31 | 2017 | 2276 | 2.430 |
Why?
|
| Insurance Claim Review | 22 | 2024 | 746 | 2.370 |
Why?
|
| Arthritis, Rheumatoid | 29 | 2022 | 3777 | 2.230 |
Why?
|
| Antirheumatic Agents | 20 | 2022 | 1377 | 2.220 |
Why?
|
| British Columbia | 36 | 2012 | 240 | 2.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 45 | 2024 | 12241 | 2.200 |
Why?
|
| Cohort Studies | 142 | 2024 | 41795 | 2.150 |
Why?
|
| Antipsychotic Agents | 24 | 2017 | 3080 | 2.100 |
Why?
|
| Epidemiologic Research Design | 12 | 2014 | 368 | 2.080 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 12 | 2018 | 495 | 2.040 |
Why?
|
| Cost Sharing | 16 | 2012 | 409 | 1.930 |
Why?
|
| Medicare Part D | 11 | 2013 | 358 | 1.890 |
Why?
|
| Antithrombins | 8 | 2020 | 294 | 1.880 |
Why?
|
| Drug Prescriptions | 27 | 2022 | 1673 | 1.780 |
Why?
|
| Delivery of Health Care | 19 | 2024 | 5375 | 1.730 |
Why?
|
| Atrial Fibrillation | 19 | 2024 | 5168 | 1.720 |
Why?
|
| Medicare | 65 | 2024 | 6881 | 1.710 |
Why?
|
| Decision Making | 15 | 2020 | 3953 | 1.680 |
Why?
|
| United States | 162 | 2024 | 73150 | 1.630 |
Why?
|
| Hypoglycemic Agents | 35 | 2024 | 3108 | 1.620 |
Why?
|
| Data Interpretation, Statistical | 22 | 2024 | 2708 | 1.610 |
Why?
|
| Humans | 510 | 2024 | 768393 | 1.600 |
Why?
|
| Drug Costs | 20 | 2019 | 1196 | 1.580 |
Why?
|
| Aged | 248 | 2024 | 171562 | 1.580 |
Why?
|
| Models, Statistical | 26 | 2019 | 5099 | 1.540 |
Why?
|
| Hospitalization | 43 | 2024 | 10844 | 1.530 |
Why?
|
| Drug Monitoring | 8 | 2017 | 964 | 1.520 |
Why?
|
| Dermatitis, Atopic | 9 | 2024 | 733 | 1.510 |
Why?
|
| Mortality | 19 | 2024 | 2917 | 1.510 |
Why?
|
| Frail Elderly | 7 | 2021 | 775 | 1.450 |
Why?
|
| Myocardial Infarction | 38 | 2024 | 11516 | 1.450 |
Why?
|
| Stroke | 30 | 2024 | 9742 | 1.440 |
Why?
|
| Ticlopidine | 8 | 2017 | 730 | 1.440 |
Why?
|
| United States Food and Drug Administration | 13 | 2024 | 1672 | 1.440 |
Why?
|
| Evidence-Based Medicine | 14 | 2021 | 3707 | 1.420 |
Why?
|
| Prescription Drugs | 11 | 2019 | 634 | 1.370 |
Why?
|
| Cardiovascular Diseases | 42 | 2024 | 15649 | 1.370 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 24 | 2020 | 3252 | 1.350 |
Why?
|
| Prescription Fees | 10 | 2012 | 153 | 1.270 |
Why?
|
| Nursing Homes | 8 | 2015 | 1084 | 1.240 |
Why?
|
| Drug Approval | 10 | 2020 | 818 | 1.220 |
Why?
|
| Data Mining | 6 | 2021 | 560 | 1.200 |
Why?
|
| Male | 259 | 2024 | 364902 | 1.190 |
Why?
|
| Female | 274 | 2024 | 397089 | 1.180 |
Why?
|
| Medical Record Linkage | 4 | 2018 | 286 | 1.170 |
Why?
|
| Treatment Outcome | 78 | 2024 | 65379 | 1.170 |
Why?
|
| Benzhydryl Compounds | 8 | 2024 | 940 | 1.170 |
Why?
|
| Glucosides | 7 | 2024 | 533 | 1.160 |
Why?
|
| Gastrointestinal Hemorrhage | 10 | 2021 | 1126 | 1.160 |
Why?
|
| Pennsylvania | 22 | 2015 | 615 | 1.140 |
Why?
|
| Algorithms | 28 | 2024 | 14154 | 1.130 |
Why?
|
| Confidentiality | 5 | 2017 | 606 | 1.130 |
Why?
|
| Drug Utilization | 20 | 2020 | 1191 | 1.120 |
Why?
|
| Aged, 80 and over | 104 | 2024 | 59686 | 1.090 |
Why?
|
| Hemorrhage | 17 | 2023 | 3461 | 1.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 18 | 2022 | 1517 | 1.060 |
Why?
|
| Biological Products | 7 | 2020 | 934 | 1.030 |
Why?
|
| Colitis, Ulcerative | 6 | 2022 | 1929 | 1.010 |
Why?
|
| Comorbidity | 28 | 2020 | 10588 | 1.000 |
Why?
|
| Equipment and Supplies | 4 | 2019 | 273 | 0.970 |
Why?
|
| Thiophenes | 4 | 2014 | 569 | 0.970 |
Why?
|
| Epidemiologic Methods | 16 | 2012 | 1337 | 0.960 |
Why?
|
| Middle Aged | 156 | 2024 | 223491 | 0.950 |
Why?
|
| Medicaid | 12 | 2020 | 2842 | 0.930 |
Why?
|
| Computer Simulation | 25 | 2024 | 6277 | 0.930 |
Why?
|
| Venous Thromboembolism | 7 | 2021 | 1881 | 0.920 |
Why?
|
| Aprotinin | 3 | 2009 | 94 | 0.920 |
Why?
|
| Heart Failure | 22 | 2024 | 11858 | 0.920 |
Why?
|
| Factor XI | 1 | 2024 | 40 | 0.900 |
Why?
|
| Health Policy | 14 | 2018 | 2698 | 0.900 |
Why?
|
| Risk Factors | 86 | 2024 | 74962 | 0.890 |
Why?
|
| Psoriasis | 7 | 2024 | 926 | 0.890 |
Why?
|
| Conjunctivitis | 2 | 2022 | 153 | 0.880 |
Why?
|
| Vitiligo | 2 | 2022 | 97 | 0.880 |
Why?
|
| Statistics as Topic | 5 | 2018 | 2363 | 0.870 |
Why?
|
| Data Collection | 9 | 2024 | 3324 | 0.870 |
Why?
|
| Scientific Misconduct | 1 | 2024 | 76 | 0.860 |
Why?
|
| Antifungal Agents | 2 | 2020 | 759 | 0.840 |
Why?
|
| Immunosuppressive Agents | 9 | 2022 | 4209 | 0.840 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2024 | 4357 | 0.830 |
Why?
|
| Information Systems | 2 | 2015 | 400 | 0.830 |
Why?
|
| Cholinergic Antagonists | 3 | 2009 | 167 | 0.820 |
Why?
|
| Proportional Hazards Models | 31 | 2024 | 12558 | 0.820 |
Why?
|
| Antidepressive Agents | 9 | 2019 | 2913 | 0.820 |
Why?
|
| Technology Assessment, Biomedical | 4 | 2020 | 309 | 0.810 |
Why?
|
| Anticonvulsants | 5 | 2014 | 1923 | 0.790 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2022 | 22 | 0.790 |
Why?
|
| Adrenergic beta-Agonists | 3 | 2009 | 347 | 0.790 |
Why?
|
| Medication Adherence | 11 | 2018 | 2189 | 0.790 |
Why?
|
| Patient Compliance | 14 | 2010 | 2693 | 0.780 |
Why?
|
| Time Factors | 41 | 2024 | 40272 | 0.780 |
Why?
|
| Calibration | 7 | 2024 | 823 | 0.760 |
Why?
|
| Biomedical Research | 5 | 2019 | 3464 | 0.760 |
Why?
|
| Pyridones | 6 | 2021 | 818 | 0.750 |
Why?
|
| Pharmaceutical Preparations | 7 | 2021 | 1088 | 0.750 |
Why?
|
| Drug Substitution | 5 | 2021 | 291 | 0.740 |
Why?
|
| Drugs, Generic | 6 | 2019 | 454 | 0.740 |
Why?
|
| Psychotropic Drugs | 3 | 2014 | 884 | 0.740 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2022 | 124 | 0.730 |
Why?
|
| Patient-Centered Care | 5 | 2014 | 1447 | 0.730 |
Why?
|
| Economics, Pharmaceutical | 6 | 2020 | 88 | 0.730 |
Why?
|
| Pyrazoles | 10 | 2021 | 2021 | 0.730 |
Why?
|
| Incidence | 37 | 2024 | 21544 | 0.730 |
Why?
|
| Hepatorenal Syndrome | 1 | 2021 | 76 | 0.710 |
Why?
|
| Bone Density Conservation Agents | 5 | 2024 | 797 | 0.690 |
Why?
|
| Methotrexate | 8 | 2024 | 1722 | 0.690 |
Why?
|
| Hepatic Encephalopathy | 1 | 2021 | 144 | 0.690 |
Why?
|
| Atrial Appendage | 1 | 2024 | 285 | 0.690 |
Why?
|
| Diabetic Ketoacidosis | 2 | 2021 | 255 | 0.680 |
Why?
|
| Risk Adjustment | 7 | 2015 | 603 | 0.680 |
Why?
|
| Patient Acceptance of Health Care | 9 | 2024 | 3231 | 0.680 |
Why?
|
| Proton Pump Inhibitors | 5 | 2013 | 553 | 0.670 |
Why?
|
| Heart Failure, Systolic | 1 | 2021 | 135 | 0.670 |
Why?
|
| Cyclooxygenase Inhibitors | 7 | 2005 | 361 | 0.670 |
Why?
|
| Fungemia | 1 | 2020 | 57 | 0.670 |
Why?
|
| Adult | 103 | 2024 | 223640 | 0.670 |
Why?
|
| Administration, Oral | 15 | 2023 | 4039 | 0.660 |
Why?
|
| Research | 5 | 2020 | 1981 | 0.660 |
Why?
|
| Deductibles and Coinsurance | 5 | 2011 | 316 | 0.650 |
Why?
|
| Homes for the Aged | 2 | 2012 | 273 | 0.650 |
Why?
|
| Hemostatics | 3 | 2019 | 246 | 0.650 |
Why?
|
| Logistic Models | 28 | 2020 | 13323 | 0.650 |
Why?
|
| Dementia | 10 | 2015 | 2729 | 0.640 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2021 | 215 | 0.640 |
Why?
|
| New Jersey | 11 | 2015 | 296 | 0.640 |
Why?
|
| Peritonitis | 1 | 2021 | 368 | 0.640 |
Why?
|
| Medical Informatics Applications | 1 | 2021 | 180 | 0.640 |
Why?
|
| Rhabdomyolysis | 4 | 2019 | 152 | 0.630 |
Why?
|
| Opportunistic Infections | 4 | 2020 | 375 | 0.630 |
Why?
|
| Causality | 7 | 2024 | 1255 | 0.630 |
Why?
|
| Databases as Topic | 6 | 2017 | 475 | 0.630 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2018 | 2763 | 0.620 |
Why?
|
| Embolism | 4 | 2023 | 401 | 0.620 |
Why?
|
| Bacterial Infections | 5 | 2020 | 1397 | 0.610 |
Why?
|
| Bronchodilator Agents | 4 | 2024 | 519 | 0.610 |
Why?
|
| Risk Assessment | 40 | 2024 | 24318 | 0.610 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2019 | 98 | 0.610 |
Why?
|
| Crohn Disease | 4 | 2022 | 2293 | 0.610 |
Why?
|
| Hidradenitis Suppurativa | 4 | 2024 | 176 | 0.600 |
Why?
|
| Neprilysin | 1 | 2021 | 487 | 0.600 |
Why?
|
| Registries | 9 | 2024 | 8379 | 0.600 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2022 | 1066 | 0.600 |
Why?
|
| Diabetes Mellitus | 10 | 2021 | 5891 | 0.600 |
Why?
|
| Gastrointestinal Agents | 3 | 2022 | 510 | 0.600 |
Why?
|
| Drug Therapy, Combination | 11 | 2021 | 6318 | 0.590 |
Why?
|
| Insurance Coverage | 8 | 2015 | 1946 | 0.590 |
Why?
|
| Amphetamine | 1 | 2019 | 225 | 0.590 |
Why?
|
| Cause of Death | 10 | 2024 | 3728 | 0.590 |
Why?
|
| Drug Utilization Review | 8 | 2014 | 248 | 0.580 |
Why?
|
| Cross-Over Studies | 10 | 2019 | 2106 | 0.580 |
Why?
|
| International Classification of Diseases | 10 | 2024 | 924 | 0.580 |
Why?
|
| Depressive Disorder | 5 | 2010 | 3736 | 0.580 |
Why?
|
| Longitudinal Studies | 19 | 2024 | 14784 | 0.570 |
Why?
|
| Health Status Indicators | 2 | 2019 | 971 | 0.570 |
Why?
|
| Neoplasms | 9 | 2024 | 22385 | 0.570 |
Why?
|
| Diabetic Angiopathies | 2 | 2020 | 806 | 0.570 |
Why?
|
| Automation | 3 | 2015 | 588 | 0.570 |
Why?
|
| Ramipril | 1 | 2018 | 102 | 0.570 |
Why?
|
| Metformin | 8 | 2022 | 911 | 0.560 |
Why?
|
| Advisory Committees | 5 | 2022 | 797 | 0.560 |
Why?
|
| Patient Selection | 8 | 2018 | 4266 | 0.560 |
Why?
|
| Myocarditis | 1 | 2024 | 803 | 0.550 |
Why?
|
| Patient Admission | 8 | 2009 | 1367 | 0.550 |
Why?
|
| Suicide, Attempted | 3 | 2010 | 1409 | 0.550 |
Why?
|
| Retrospective Studies | 57 | 2024 | 81801 | 0.550 |
Why?
|
| Privacy | 2 | 2017 | 233 | 0.550 |
Why?
|
| International Normalized Ratio | 2 | 2021 | 382 | 0.550 |
Why?
|
| Activities of Daily Living | 5 | 2020 | 2433 | 0.550 |
Why?
|
| Information Storage and Retrieval | 2 | 2019 | 824 | 0.550 |
Why?
|
| Lactones | 5 | 2015 | 316 | 0.540 |
Why?
|
| Information Dissemination | 4 | 2024 | 1137 | 0.540 |
Why?
|
| Hip Fractures | 7 | 2024 | 996 | 0.540 |
Why?
|
| Sulfonylurea Compounds | 7 | 2021 | 220 | 0.540 |
Why?
|
| Echinocandins | 1 | 2016 | 53 | 0.530 |
Why?
|
| Government Regulation | 2 | 2018 | 525 | 0.530 |
Why?
|
| Lipopeptides | 1 | 2016 | 71 | 0.520 |
Why?
|
| Health Services | 5 | 2010 | 756 | 0.520 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2016 | 391 | 0.520 |
Why?
|
| Continuity of Patient Care | 3 | 2021 | 1076 | 0.520 |
Why?
|
| Geriatric Assessment | 6 | 2020 | 1422 | 0.520 |
Why?
|
| Germany | 13 | 2024 | 882 | 0.520 |
Why?
|
| Health Services for the Aged | 4 | 2009 | 258 | 0.520 |
Why?
|
| Anti-Ulcer Agents | 4 | 2013 | 112 | 0.510 |
Why?
|
| Multivariate Analysis | 14 | 2014 | 12092 | 0.500 |
Why?
|
| Odds Ratio | 18 | 2021 | 9682 | 0.500 |
Why?
|
| Matched-Pair Analysis | 3 | 2021 | 286 | 0.500 |
Why?
|
| Gout Suppressants | 2 | 2015 | 177 | 0.500 |
Why?
|
| Reproducibility of Results | 28 | 2024 | 20224 | 0.500 |
Why?
|
| Risk | 21 | 2019 | 9636 | 0.500 |
Why?
|
| Adrenergic beta-Antagonists | 7 | 2016 | 1244 | 0.500 |
Why?
|
| Gastrointestinal Diseases | 6 | 2012 | 1207 | 0.490 |
Why?
|
| Anemia, Sickle Cell | 2 | 2020 | 1065 | 0.490 |
Why?
|
| National Health Programs | 6 | 2010 | 442 | 0.480 |
Why?
|
| Guidelines as Topic | 8 | 2024 | 1397 | 0.480 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2015 | 1735 | 0.480 |
Why?
|
| Benzimidazoles | 3 | 2014 | 864 | 0.470 |
Why?
|
| Suicide | 3 | 2010 | 1607 | 0.470 |
Why?
|
| Blood Coagulation | 2 | 2018 | 1161 | 0.470 |
Why?
|
| Young Adult | 36 | 2024 | 60049 | 0.470 |
Why?
|
| Methylphenidate | 1 | 2019 | 491 | 0.470 |
Why?
|
| Bariatric Surgery | 2 | 2024 | 1013 | 0.470 |
Why?
|
| Sulfones | 5 | 2015 | 448 | 0.460 |
Why?
|
| Cardiovascular Agents | 4 | 2018 | 849 | 0.460 |
Why?
|
| Clinical Trials as Topic | 8 | 2019 | 8051 | 0.450 |
Why?
|
| Drug Therapy | 6 | 2012 | 504 | 0.450 |
Why?
|
| Piperazines | 4 | 2014 | 2552 | 0.440 |
Why?
|
| Adolescent | 45 | 2024 | 89184 | 0.440 |
Why?
|
| Ketolides | 2 | 2014 | 12 | 0.440 |
Why?
|
| Drug Evaluation | 3 | 2015 | 642 | 0.440 |
Why?
|
| Research Report | 3 | 2022 | 369 | 0.430 |
Why?
|
| Fees, Pharmaceutical | 3 | 2014 | 66 | 0.430 |
Why?
|
| Angioedema | 5 | 2019 | 184 | 0.430 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 213 | 0.430 |
Why?
|
| Decision Making, Organizational | 3 | 2019 | 136 | 0.430 |
Why?
|
| Financing, Personal | 3 | 2012 | 310 | 0.420 |
Why?
|
| Secondary Prevention | 5 | 2018 | 1476 | 0.420 |
Why?
|
| Mycoses | 1 | 2016 | 386 | 0.420 |
Why?
|
| beta-Alanine | 2 | 2014 | 82 | 0.420 |
Why?
|
| Renal Insufficiency | 2 | 2009 | 809 | 0.410 |
Why?
|
| Thrombophilia | 1 | 2015 | 306 | 0.410 |
Why?
|
| Simvastatin | 2 | 2012 | 346 | 0.410 |
Why?
|
| Choice Behavior | 2 | 2019 | 848 | 0.410 |
Why?
|
| Medically Uninsured | 3 | 2013 | 841 | 0.410 |
Why?
|
| Epidemiologic Studies | 3 | 2006 | 678 | 0.410 |
Why?
|
| Brain Ischemia | 6 | 2021 | 3008 | 0.410 |
Why?
|
| Steroids | 2 | 2009 | 937 | 0.410 |
Why?
|
| Medical Assistance | 3 | 2012 | 108 | 0.400 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 8 | 2024 | 3243 | 0.400 |
Why?
|
| Hospital Departments | 2 | 2003 | 135 | 0.400 |
Why?
|
| Azithromycin | 2 | 2019 | 200 | 0.400 |
Why?
|
| Arthritis | 3 | 2020 | 684 | 0.400 |
Why?
|
| Fractures, Bone | 6 | 2019 | 2062 | 0.400 |
Why?
|
| Patient Preference | 3 | 2020 | 947 | 0.400 |
Why?
|
| Pharmacies | 3 | 2010 | 171 | 0.390 |
Why?
|
| Policy Making | 3 | 2019 | 545 | 0.390 |
Why?
|
| Decision Support Techniques | 4 | 2017 | 2006 | 0.390 |
Why?
|
| Glucocorticoids | 5 | 2009 | 2168 | 0.390 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 700 | 0.390 |
Why?
|
| Blood Loss, Surgical | 3 | 2015 | 643 | 0.390 |
Why?
|
| Coronary Artery Bypass | 5 | 2015 | 2194 | 0.390 |
Why?
|
| Computer Communication Networks | 2 | 2014 | 295 | 0.390 |
Why?
|
| Health Services Accessibility | 5 | 2018 | 5512 | 0.380 |
Why?
|
| Azetidines | 1 | 2012 | 143 | 0.380 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2014 | 284 | 0.380 |
Why?
|
| Health Expenditures | 10 | 2013 | 2395 | 0.370 |
Why?
|
| Predictive Value of Tests | 18 | 2024 | 15455 | 0.360 |
Why?
|
| Regression Analysis | 12 | 2018 | 6350 | 0.360 |
Why?
|
| Peptic Ulcer | 3 | 2017 | 222 | 0.360 |
Why?
|
| Alopecia Areata | 2 | 2024 | 130 | 0.360 |
Why?
|
| Utilization Review | 4 | 2010 | 384 | 0.350 |
Why?
|
| Central Nervous System Stimulants | 1 | 2019 | 1181 | 0.350 |
Why?
|
| Insurance, Health, Reimbursement | 3 | 2017 | 390 | 0.350 |
Why?
|
| Canada | 10 | 2012 | 2139 | 0.350 |
Why?
|
| Academies and Institutes | 1 | 2012 | 326 | 0.340 |
Why?
|
| Morpholines | 2 | 2014 | 584 | 0.340 |
Why?
|
| Myocardial Revascularization | 3 | 2016 | 796 | 0.340 |
Why?
|
| Gout | 2 | 2015 | 621 | 0.340 |
Why?
|
| Models, Theoretical | 6 | 2016 | 3579 | 0.340 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2009 | 36 | 0.340 |
Why?
|
| Immunologic Factors | 7 | 2024 | 1597 | 0.340 |
Why?
|
| Acute Coronary Syndrome | 3 | 2018 | 2192 | 0.340 |
Why?
|
| Hospital Mortality | 9 | 2018 | 5367 | 0.330 |
Why?
|
| Pharmaceutical Services | 4 | 2020 | 143 | 0.330 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2016 | 2044 | 0.330 |
Why?
|
| Age Factors | 17 | 2020 | 18471 | 0.330 |
Why?
|
| Cost-Benefit Analysis | 7 | 2015 | 5538 | 0.330 |
Why?
|
| Health Services Research | 5 | 2005 | 1817 | 0.330 |
Why?
|
| Lipoproteins, LDL | 1 | 2012 | 643 | 0.330 |
Why?
|
| Program Development | 3 | 2020 | 1298 | 0.330 |
Why?
|
| Likelihood Functions | 5 | 2018 | 993 | 0.330 |
Why?
|
| Cystoscopy | 2 | 2000 | 132 | 0.320 |
Why?
|
| Osteoporosis | 5 | 2012 | 1606 | 0.320 |
Why?
|
| Asthma | 5 | 2022 | 6280 | 0.320 |
Why?
|
| Medication Therapy Management | 2 | 2021 | 131 | 0.310 |
Why?
|
| Community Pharmacy Services | 3 | 2018 | 52 | 0.310 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2018 | 429 | 0.300 |
Why?
|
| Diphosphonates | 3 | 2012 | 635 | 0.300 |
Why?
|
| Probability | 5 | 2019 | 2482 | 0.300 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2008 | 65 | 0.300 |
Why?
|
| Lipoproteins, HDL | 1 | 2012 | 682 | 0.300 |
Why?
|
| Rural Health | 1 | 2009 | 300 | 0.300 |
Why?
|
| Hydroxychloroquine | 5 | 2022 | 426 | 0.300 |
Why?
|
| Infusions, Parenteral | 2 | 2020 | 397 | 0.300 |
Why?
|
| Cost Control | 8 | 2017 | 627 | 0.300 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 789 | 0.290 |
Why?
|
| Cost Savings | 7 | 2011 | 915 | 0.290 |
Why?
|
| Therapeutic Equivalency | 5 | 2010 | 134 | 0.290 |
Why?
|
| Internal Medicine | 4 | 2003 | 1057 | 0.290 |
Why?
|
| Drug Combinations | 4 | 2024 | 2079 | 0.280 |
Why?
|
| Urban Health | 1 | 2009 | 535 | 0.280 |
Why?
|
| Drug Interactions | 6 | 2019 | 1420 | 0.280 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 2336 | 0.280 |
Why?
|
| Administration, Inhalation | 6 | 2024 | 1169 | 0.280 |
Why?
|
| Death, Sudden | 1 | 2009 | 301 | 0.280 |
Why?
|
| Costs and Cost Analysis | 5 | 2009 | 1669 | 0.280 |
Why?
|
| Angioplasty | 1 | 2009 | 357 | 0.280 |
Why?
|
| Fractures, Ununited | 1 | 2008 | 176 | 0.270 |
Why?
|
| Quality Indicators, Health Care | 2 | 2017 | 1813 | 0.270 |
Why?
|
| Sentinel Surveillance | 2 | 2024 | 292 | 0.270 |
Why?
|
| Drug Design | 1 | 2011 | 1046 | 0.270 |
Why?
|
| Analgesics, Opioid | 3 | 2013 | 3836 | 0.270 |
Why?
|
| Monte Carlo Method | 8 | 2021 | 1261 | 0.260 |
Why?
|
| Sulfonamides | 5 | 2014 | 1980 | 0.260 |
Why?
|
| Phenylcarbamates | 1 | 2006 | 38 | 0.260 |
Why?
|
| Residence Characteristics | 4 | 2013 | 2122 | 0.260 |
Why?
|
| Renal Dialysis | 5 | 2019 | 1802 | 0.260 |
Why?
|
| Osteoarthritis | 4 | 2010 | 1070 | 0.260 |
Why?
|
| Paroxetine | 3 | 2012 | 181 | 0.260 |
Why?
|
| Galantamine | 1 | 2006 | 33 | 0.260 |
Why?
|
| Neutropenia | 1 | 2011 | 893 | 0.260 |
Why?
|
| Follow-Up Studies | 18 | 2020 | 39407 | 0.250 |
Why?
|
| Kidney Failure, Chronic | 5 | 2023 | 2491 | 0.250 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 3941 | 0.250 |
Why?
|
| Stroke Volume | 2 | 2022 | 5619 | 0.250 |
Why?
|
| Omeprazole | 1 | 2006 | 106 | 0.250 |
Why?
|
| Family Practice | 1 | 2008 | 511 | 0.250 |
Why?
|
| Pain | 2 | 2010 | 5103 | 0.250 |
Why?
|
| Epilepsy | 2 | 2012 | 3326 | 0.250 |
Why?
|
| Thromboembolism | 3 | 2024 | 1004 | 0.250 |
Why?
|
| Humeral Fractures | 1 | 2008 | 283 | 0.250 |
Why?
|
| Polypharmacy | 4 | 2015 | 307 | 0.250 |
Why?
|
| Indans | 1 | 2006 | 92 | 0.250 |
Why?
|
| Pyridines | 5 | 2017 | 2889 | 0.250 |
Why?
|
| Bayes Theorem | 3 | 2018 | 2353 | 0.240 |
Why?
|
| Tacrolimus | 1 | 2009 | 750 | 0.240 |
Why?
|
| Chlorobenzenes | 1 | 2024 | 31 | 0.240 |
Why?
|
| Quinuclidines | 1 | 2024 | 27 | 0.240 |
Why?
|
| Physicians, Family | 2 | 2009 | 349 | 0.240 |
Why?
|
| Benzyl Alcohols | 1 | 2024 | 33 | 0.240 |
Why?
|
| Rate Setting and Review | 2 | 2002 | 41 | 0.240 |
Why?
|
| Behavioral Symptoms | 1 | 2006 | 188 | 0.240 |
Why?
|
| Hypnotics and Sedatives | 3 | 2017 | 1188 | 0.240 |
Why?
|
| Sodium | 7 | 2022 | 1594 | 0.240 |
Why?
|
| Sensitivity and Specificity | 12 | 2020 | 14737 | 0.240 |
Why?
|
| Osteoporotic Fractures | 2 | 2024 | 417 | 0.230 |
Why?
|
| Antifibrinolytic Agents | 1 | 2008 | 289 | 0.230 |
Why?
|
| Learning | 1 | 2014 | 1761 | 0.230 |
Why?
|
| Muscarinic Antagonists | 2 | 2018 | 135 | 0.230 |
Why?
|
| Severity of Illness Index | 13 | 2023 | 15939 | 0.230 |
Why?
|
| Program Evaluation | 5 | 2006 | 2505 | 0.230 |
Why?
|
| Concurrent Review | 2 | 2002 | 13 | 0.230 |
Why?
|
| Self-Injurious Behavior | 1 | 2010 | 568 | 0.230 |
Why?
|
| Liver Neoplasms | 2 | 2020 | 4365 | 0.230 |
Why?
|
| Case-Control Studies | 19 | 2020 | 22296 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2017 | 10776 | 0.230 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 241 | 0.230 |
Why?
|
| Respiratory Tract Diseases | 2 | 2008 | 748 | 0.220 |
Why?
|
| Inflammatory Bowel Diseases | 5 | 2022 | 2442 | 0.220 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 1943 | 0.220 |
Why?
|
| Blood Glucose | 2 | 2018 | 6430 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2022 | 2257 | 0.220 |
Why?
|
| Dihydropyridines | 1 | 2003 | 67 | 0.220 |
Why?
|
| Violence | 1 | 2010 | 938 | 0.220 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2009 | 1097 | 0.220 |
Why?
|
| Clinical Coding | 3 | 2021 | 186 | 0.220 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2019 | 3743 | 0.220 |
Why?
|
| Prospective Studies | 17 | 2020 | 54920 | 0.220 |
Why?
|
| Confidence Intervals | 7 | 2017 | 2931 | 0.210 |
Why?
|
| Public Health Informatics | 1 | 2004 | 109 | 0.210 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 2296 | 0.210 |
Why?
|
| Urinary Tract Infections | 2 | 2019 | 806 | 0.210 |
Why?
|
| Calcium Channel Blockers | 2 | 2003 | 692 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 4 | 2023 | 9261 | 0.210 |
Why?
|
| Coronary Disease | 3 | 2013 | 5924 | 0.210 |
Why?
|
| Breast Neoplasms | 4 | 2023 | 21162 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2015 | 4047 | 0.210 |
Why?
|
| Coronary Stenosis | 1 | 2009 | 802 | 0.210 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2009 | 1724 | 0.210 |
Why?
|
| Drug-Eluting Stents | 1 | 2009 | 681 | 0.200 |
Why?
|
| Healthcare Disparities | 3 | 2014 | 3413 | 0.200 |
Why?
|
| Medical Records Systems, Computerized | 3 | 2009 | 1196 | 0.200 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2021 | 1890 | 0.200 |
Why?
|
| Benzodiazepines | 5 | 2011 | 1139 | 0.200 |
Why?
|
| Medical Records | 4 | 2005 | 1412 | 0.200 |
Why?
|
| Azathioprine | 2 | 2021 | 354 | 0.200 |
Why?
|
| Hepatitis | 1 | 2024 | 228 | 0.200 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 1795 | 0.190 |
Why?
|
| Length of Stay | 8 | 2017 | 6519 | 0.190 |
Why?
|
| Health Services Misuse | 2 | 2002 | 249 | 0.190 |
Why?
|
| Medical Oncology | 3 | 2022 | 2349 | 0.190 |
Why?
|
| Glucose | 9 | 2022 | 4352 | 0.190 |
Why?
|
| Prognosis | 8 | 2018 | 30022 | 0.190 |
Why?
|
| Migraine Disorders | 2 | 2012 | 1713 | 0.190 |
Why?
|
| Insurance, Health | 5 | 2020 | 2518 | 0.190 |
Why?
|
| Histamine H2 Antagonists | 2 | 2013 | 169 | 0.190 |
Why?
|
| Hypertension | 9 | 2018 | 8615 | 0.180 |
Why?
|
| Fibrinolytic Agents | 2 | 2015 | 2074 | 0.180 |
Why?
|
| Glucagon-Like Peptide 1 | 5 | 2022 | 367 | 0.180 |
Why?
|
| Diagnosis-Related Groups | 4 | 2007 | 448 | 0.180 |
Why?
|
| Treatment Refusal | 2 | 2007 | 432 | 0.180 |
Why?
|
| Physicians | 4 | 2011 | 4614 | 0.180 |
Why?
|
| Education, Medical, Continuing | 1 | 2006 | 829 | 0.180 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2009 | 1568 | 0.180 |
Why?
|
| Software | 6 | 2024 | 4453 | 0.180 |
Why?
|
| Fluvoxamine | 2 | 2010 | 78 | 0.170 |
Why?
|
| Insurance Claim Reporting | 3 | 2007 | 166 | 0.170 |
Why?
|
| Systemic Vasculitis | 1 | 2020 | 37 | 0.170 |
Why?
|
| France | 1 | 2021 | 497 | 0.170 |
Why?
|
| Fournier Gangrene | 1 | 2019 | 22 | 0.170 |
Why?
|
| Macrolides | 1 | 2021 | 205 | 0.170 |
Why?
|
| Total Quality Management | 1 | 2001 | 265 | 0.170 |
Why?
|
| Lymphoma | 1 | 2009 | 1907 | 0.170 |
Why?
|
| Scleroderma, Localized | 1 | 2020 | 85 | 0.170 |
Why?
|
| Hospitals | 4 | 2015 | 3906 | 0.170 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2019 | 87 | 0.170 |
Why?
|
| Policy | 1 | 2023 | 514 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 1813 | 0.160 |
Why?
|
| Ascites | 1 | 2021 | 338 | 0.160 |
Why?
|
| Defibrillators, Implantable | 1 | 2009 | 1498 | 0.160 |
Why?
|
| Thiazoles | 3 | 2017 | 1542 | 0.160 |
Why?
|
| Cyclosporine | 1 | 2022 | 779 | 0.160 |
Why?
|
| Multiple Sclerosis | 3 | 2024 | 3247 | 0.160 |
Why?
|
| Cross-Sectional Studies | 14 | 2020 | 26375 | 0.160 |
Why?
|
| Hyperphosphatemia | 1 | 2019 | 38 | 0.160 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2009 | 1421 | 0.160 |
Why?
|
| Reimbursement, Incentive | 1 | 2004 | 548 | 0.160 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2009 | 1402 | 0.160 |
Why?
|
| Gastrointestinal Tract | 3 | 2013 | 839 | 0.160 |
Why?
|
| Terminology as Topic | 3 | 2019 | 1539 | 0.160 |
Why?
|
| Postoperative Complications | 5 | 2015 | 15881 | 0.160 |
Why?
|
| Guideline Adherence | 5 | 2012 | 2240 | 0.160 |
Why?
|
| European Union | 1 | 2019 | 157 | 0.160 |
Why?
|
| Self-Assessment | 1 | 2001 | 401 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2010 | 2529 | 0.150 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2004 | 1163 | 0.150 |
Why?
|
| Thalidomide | 1 | 2024 | 886 | 0.150 |
Why?
|
| Age Distribution | 5 | 2020 | 2877 | 0.150 |
Why?
|
| Altitude | 2 | 2011 | 164 | 0.150 |
Why?
|
| Stents | 2 | 2018 | 3201 | 0.150 |
Why?
|
| Sjogren's Syndrome | 1 | 2020 | 241 | 0.150 |
Why?
|
| Peptide Fragments | 2 | 2015 | 5151 | 0.150 |
Why?
|
| Mental Health Services | 1 | 2010 | 1731 | 0.150 |
Why?
|
| Calcium Phosphates | 1 | 2019 | 173 | 0.150 |
Why?
|
| Vitamin K | 2 | 2018 | 314 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2013 | 6541 | 0.150 |
Why?
|
| Immunization Programs | 1 | 2000 | 267 | 0.150 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2009 | 139 | 0.140 |
Why?
|
| Chelating Agents | 1 | 2019 | 385 | 0.140 |
Why?
|
| Managed Care Programs | 2 | 2020 | 942 | 0.140 |
Why?
|
| Attitude of Health Personnel | 2 | 2002 | 3922 | 0.140 |
Why?
|
| Perioperative Care | 2 | 2015 | 1045 | 0.140 |
Why?
|
| Lung Diseases | 1 | 2008 | 1925 | 0.140 |
Why?
|
| Anti-Obesity Agents | 1 | 2021 | 240 | 0.140 |
Why?
|
| Pneumonia | 4 | 2024 | 2163 | 0.140 |
Why?
|
| Prospective Payment System | 1 | 2018 | 136 | 0.140 |
Why?
|
| Connective Tissue Diseases | 1 | 2020 | 285 | 0.140 |
Why?
|
| Seizures | 1 | 2010 | 3000 | 0.140 |
Why?
|
| Femoral Fractures | 2 | 2011 | 376 | 0.140 |
Why?
|
| Atherosclerosis | 2 | 2024 | 3431 | 0.140 |
Why?
|
| Citalopram | 2 | 2010 | 401 | 0.140 |
Why?
|
| Referral and Consultation | 3 | 2023 | 3627 | 0.140 |
Why?
|
| Forecasting | 3 | 2018 | 2948 | 0.140 |
Why?
|
| Liver Cirrhosis | 3 | 2023 | 1959 | 0.140 |
Why?
|
| Piperidines | 1 | 2006 | 1659 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 1407 | 0.140 |
Why?
|
| Mandelic Acids | 2 | 2019 | 46 | 0.140 |
Why?
|
| Hyponatremia | 1 | 2019 | 280 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2021 | 620 | 0.140 |
Why?
|
| Hypolipidemic Agents | 3 | 2012 | 609 | 0.140 |
Why?
|
| Phototherapy | 1 | 2020 | 367 | 0.140 |
Why?
|
| Health Status | 2 | 2007 | 4094 | 0.140 |
Why?
|
| Inflammation | 2 | 2020 | 10863 | 0.140 |
Why?
|
| Drug Labeling | 2 | 2009 | 250 | 0.140 |
Why?
|
| Hospital Costs | 1 | 2003 | 959 | 0.130 |
Why?
|
| Health Communication | 1 | 2019 | 216 | 0.130 |
Why?
|
| Patient Participation | 1 | 2005 | 1448 | 0.130 |
Why?
|
| Child Welfare | 1 | 2000 | 523 | 0.130 |
Why?
|
| Fluoxetine | 2 | 2010 | 735 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2006 | 6971 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2009 | 3681 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 780 | 0.130 |
Why?
|
| Child | 16 | 2023 | 80891 | 0.130 |
Why?
|
| Drug Repositioning | 1 | 2018 | 244 | 0.130 |
Why?
|
| Risperidone | 3 | 2017 | 383 | 0.130 |
Why?
|
| Anemia | 3 | 2011 | 1519 | 0.130 |
Why?
|
| Legislation, Drug | 1 | 2018 | 216 | 0.130 |
Why?
|
| Sex Distribution | 4 | 2010 | 2281 | 0.130 |
Why?
|
| Trust | 1 | 2020 | 532 | 0.130 |
Why?
|
| Thrombolytic Therapy | 1 | 2004 | 2050 | 0.120 |
Why?
|
| Peer Review | 1 | 2017 | 219 | 0.120 |
Why?
|
| Receptor, erbB-2 | 2 | 2023 | 2588 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 4570 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 1905 | 0.120 |
Why?
|
| Public Opinion | 1 | 2019 | 486 | 0.120 |
Why?
|
| Erythropoietin | 2 | 2011 | 719 | 0.120 |
Why?
|
| Anaphylaxis | 1 | 2022 | 758 | 0.120 |
Why?
|
| Independent Living | 1 | 2019 | 580 | 0.120 |
Why?
|
| Xanthine Oxidase | 1 | 2015 | 69 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 1180 | 0.120 |
Why?
|
| Quality Control | 1 | 2017 | 833 | 0.120 |
Why?
|
| Cerebral Hemorrhage | 2 | 2016 | 2653 | 0.120 |
Why?
|
| ROC Curve | 3 | 2017 | 3623 | 0.120 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2014 | 88 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 11854 | 0.120 |
Why?
|
| Chronic Disease | 7 | 2022 | 9379 | 0.120 |
Why?
|
| Remission Induction | 1 | 2020 | 2407 | 0.110 |
Why?
|
| Antihypertensive Agents | 4 | 2012 | 2027 | 0.110 |
Why?
|
| Dibenzothiazepines | 2 | 2012 | 102 | 0.110 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2014 | 105 | 0.110 |
Why?
|
| Income | 4 | 2014 | 1877 | 0.110 |
Why?
|
| Licensure | 1 | 2015 | 127 | 0.110 |
Why?
|
| Oseltamivir | 1 | 2014 | 75 | 0.110 |
Why?
|
| Thinking | 1 | 2017 | 320 | 0.110 |
Why?
|
| Patient Satisfaction | 2 | 2009 | 3486 | 0.110 |
Why?
|
| Kidney | 1 | 2009 | 7064 | 0.110 |
Why?
|
| Marketing | 2 | 2014 | 224 | 0.110 |
Why?
|
| Primary Health Care | 2 | 2010 | 4748 | 0.110 |
Why?
|
| Thiazolidinediones | 3 | 2014 | 462 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2017 | 1642 | 0.110 |
Why?
|
| Alzheimer Disease | 3 | 2022 | 8747 | 0.110 |
Why?
|
| Hirudins | 2 | 2015 | 179 | 0.110 |
Why?
|
| Sex Factors | 9 | 2020 | 10654 | 0.110 |
Why?
|
| Sample Size | 2 | 2019 | 848 | 0.110 |
Why?
|
| Biostatistics | 1 | 2014 | 165 | 0.110 |
Why?
|
| Recombinant Proteins | 3 | 2015 | 6510 | 0.100 |
Why?
|
| Emergency Service, Hospital | 4 | 2011 | 7955 | 0.100 |
Why?
|
| Enzyme Induction | 1 | 2013 | 455 | 0.100 |
Why?
|
| Selection Bias | 1 | 2014 | 360 | 0.100 |
Why?
|
| Communication | 2 | 2019 | 3912 | 0.100 |
Why?
|
| Narcotics | 2 | 2005 | 334 | 0.100 |
Why?
|
| Terminally Ill | 1 | 2015 | 240 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 4 | 2017 | 7463 | 0.100 |
Why?
|
| Obesity | 8 | 2024 | 13084 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 2709 | 0.100 |
Why?
|
| Linear Models | 6 | 2011 | 5878 | 0.100 |
Why?
|
| Hyperlipidemias | 2 | 2009 | 773 | 0.100 |
Why?
|
| Stockings, Compression | 1 | 2012 | 36 | 0.100 |
Why?
|
| Gastric Juice | 1 | 2012 | 59 | 0.100 |
Why?
|
| Anticholesteremic Agents | 3 | 2012 | 972 | 0.100 |
Why?
|
| Allopurinol | 1 | 2013 | 198 | 0.100 |
Why?
|
| Colchicine | 1 | 2013 | 257 | 0.100 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 1736 | 0.100 |
Why?
|
| Prevalence | 6 | 2024 | 15872 | 0.100 |
Why?
|
| Gastric Acid | 1 | 2012 | 99 | 0.100 |
Why?
|
| Lisinopril | 1 | 2012 | 60 | 0.100 |
Why?
|
| Arthroplasty, Replacement | 1 | 2015 | 310 | 0.100 |
Why?
|
| Phenylpropanolamine | 1 | 2011 | 15 | 0.100 |
Why?
|
| Health Planning Support | 1 | 2011 | 8 | 0.100 |
Why?
|
| Cephalosporins | 1 | 2013 | 200 | 0.100 |
Why?
|
| Cresols | 1 | 2011 | 26 | 0.100 |
Why?
|
| Infant | 8 | 2020 | 36510 | 0.100 |
Why?
|
| Benchmarking | 3 | 2015 | 1058 | 0.100 |
Why?
|
| Child, Preschool | 9 | 2020 | 42650 | 0.100 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 732 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 2 | 2001 | 1937 | 0.100 |
Why?
|
| Models, Biological | 2 | 2018 | 9493 | 0.090 |
Why?
|
| Medicare Part B | 1 | 2012 | 117 | 0.090 |
Why?
|
| Diabetes Complications | 2 | 2009 | 1322 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 2 | 2010 | 1364 | 0.090 |
Why?
|
| Diaphyses | 1 | 2011 | 65 | 0.090 |
Why?
|
| Filgrastim | 1 | 2011 | 131 | 0.090 |
Why?
|
| Dextropropoxyphene | 1 | 2010 | 26 | 0.090 |
Why?
|
| Urinary Incontinence, Urge | 1 | 2011 | 50 | 0.090 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 264 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2014 | 1727 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 13576 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2024 | 2029 | 0.090 |
Why?
|
| Anesthesia, Conduction | 1 | 2014 | 263 | 0.090 |
Why?
|
| Hydrocodone | 1 | 2010 | 48 | 0.090 |
Why?
|
| Disease Progression | 3 | 2021 | 13646 | 0.090 |
Why?
|
| Europe | 3 | 2020 | 3439 | 0.090 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 423 | 0.090 |
Why?
|
| Codeine | 1 | 2010 | 52 | 0.090 |
Why?
|
| Chemoprevention | 1 | 2013 | 326 | 0.090 |
Why?
|
| Nootropic Agents | 1 | 2012 | 159 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2012 | 575 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 3 | 2010 | 2181 | 0.090 |
Why?
|
| Evidence-Based Practice | 2 | 2018 | 500 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 3722 | 0.090 |
Why?
|
| Analgesics | 1 | 2017 | 1070 | 0.090 |
Why?
|
| Mental Disorders | 3 | 2009 | 6876 | 0.090 |
Why?
|
| Tramadol | 1 | 2010 | 63 | 0.090 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 344 | 0.090 |
Why?
|
| Haloperidol | 1 | 2012 | 394 | 0.090 |
Why?
|
| Ciprofloxacin | 1 | 2012 | 313 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 450 | 0.090 |
Why?
|
| Drug Recalls | 1 | 2009 | 20 | 0.080 |
Why?
|
| Health Surveys | 2 | 2019 | 4056 | 0.080 |
Why?
|
| Social Class | 1 | 2019 | 2009 | 0.080 |
Why?
|
| Vancomycin | 1 | 2013 | 505 | 0.080 |
Why?
|
| General Practitioners | 1 | 2011 | 103 | 0.080 |
Why?
|
| Office Visits | 1 | 2013 | 596 | 0.080 |
Why?
|
| Oxycodone | 1 | 2010 | 145 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2012 | 962 | 0.080 |
Why?
|
| Weight Loss | 1 | 2021 | 2713 | 0.080 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2009 | 46 | 0.080 |
Why?
|
| Health Plan Implementation | 1 | 2012 | 338 | 0.080 |
Why?
|
| Hydrochlorothiazide | 1 | 2009 | 95 | 0.080 |
Why?
|
| Sertraline | 1 | 2010 | 209 | 0.080 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2019 | 118 | 0.080 |
Why?
|
| Aminolevulinic Acid | 2 | 2000 | 150 | 0.080 |
Why?
|
| Geriatrics | 2 | 2005 | 390 | 0.080 |
Why?
|
| Publication Bias | 1 | 2009 | 159 | 0.080 |
Why?
|
| Drug Administration Schedule | 4 | 2018 | 4859 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2011 | 631 | 0.080 |
Why?
|
| Financing, Government | 1 | 2012 | 473 | 0.080 |
Why?
|
| Massachusetts | 1 | 2021 | 8902 | 0.080 |
Why?
|
| Imipramine | 1 | 2008 | 98 | 0.080 |
Why?
|
| Vaccination | 1 | 2000 | 3431 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 2783 | 0.070 |
Why?
|
| Research Personnel | 2 | 2023 | 590 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 876 | 0.070 |
Why?
|
| Least-Squares Analysis | 1 | 2008 | 368 | 0.070 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2010 | 332 | 0.070 |
Why?
|
| Heart Diseases | 2 | 2015 | 2819 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 640 | 0.070 |
Why?
|
| Socioeconomic Factors | 4 | 2012 | 7861 | 0.070 |
Why?
|
| Quality Improvement | 2 | 2014 | 3858 | 0.070 |
Why?
|
| Quality of Health Care | 3 | 2014 | 4339 | 0.070 |
Why?
|
| Self Report | 1 | 2019 | 3766 | 0.070 |
Why?
|
| Health Personnel | 1 | 2001 | 3380 | 0.070 |
Why?
|
| Long-Term Care | 2 | 2002 | 632 | 0.070 |
Why?
|
| Control Groups | 1 | 2007 | 107 | 0.070 |
Why?
|
| Medicare Part C | 1 | 2012 | 332 | 0.070 |
Why?
|
| Arthritis, Psoriatic | 1 | 2010 | 217 | 0.070 |
Why?
|
| Recurrence | 5 | 2018 | 8506 | 0.070 |
Why?
|
| Risk Management | 2 | 2015 | 558 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 2 | 2022 | 998 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2019 | 3960 | 0.070 |
Why?
|
| Contraceptive Agents, Female | 1 | 2008 | 123 | 0.070 |
Why?
|
| Database Management Systems | 1 | 2008 | 257 | 0.070 |
Why?
|
| Hematinics | 1 | 2010 | 282 | 0.070 |
Why?
|
| Anesthesia, General | 1 | 2014 | 1186 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2009 | 703 | 0.070 |
Why?
|
| Psychotic Disorders | 3 | 2013 | 3279 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2015 | 1067 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2012 | 790 | 0.070 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2008 | 187 | 0.070 |
Why?
|
| Contraception Behavior | 1 | 2008 | 187 | 0.070 |
Why?
|
| Pain Measurement | 3 | 2010 | 3581 | 0.070 |
Why?
|
| Sulfoxides | 1 | 2006 | 47 | 0.070 |
Why?
|
| Heptanoic Acids | 1 | 2008 | 344 | 0.070 |
Why?
|
| Antiviral Agents | 2 | 2020 | 3064 | 0.070 |
Why?
|
| Diclofenac | 1 | 2006 | 69 | 0.070 |
Why?
|
| Naproxen | 1 | 2006 | 101 | 0.070 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2006 | 32 | 0.070 |
Why?
|
| Clozapine | 3 | 2007 | 508 | 0.060 |
Why?
|
| Observer Variation | 3 | 2002 | 2623 | 0.060 |
Why?
|
| Smoking | 4 | 2020 | 9111 | 0.060 |
Why?
|
| Contraceptives, Oral | 1 | 2008 | 562 | 0.060 |
Why?
|
| State Health Plans | 1 | 2008 | 220 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2012 | 1024 | 0.060 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2007 | 433 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 1195 | 0.060 |
Why?
|
| Databases, Bibliographic | 1 | 2005 | 129 | 0.060 |
Why?
|
| Dry Powder Inhalers | 1 | 2024 | 10 | 0.060 |
Why?
|
| Medication Systems | 1 | 2005 | 31 | 0.060 |
Why?
|
| Emphysema | 1 | 2008 | 237 | 0.060 |
Why?
|
| Reference Values | 2 | 2002 | 4941 | 0.060 |
Why?
|
| Metered Dose Inhalers | 1 | 2024 | 28 | 0.060 |
Why?
|
| Ischemia | 1 | 2014 | 1900 | 0.060 |
Why?
|
| Ibuprofen | 1 | 2006 | 229 | 0.060 |
Why?
|
| Glycopyrrolate | 1 | 2024 | 35 | 0.060 |
Why?
|
| Random Allocation | 2 | 2007 | 2397 | 0.060 |
Why?
|
| Body Mass Index | 4 | 2024 | 13052 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2007 | 10117 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 588 | 0.060 |
Why?
|
| Pravastatin | 2 | 2006 | 393 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2014 | 2170 | 0.060 |
Why?
|
| Leukotriene Antagonists | 1 | 2005 | 124 | 0.060 |
Why?
|
| Vitamin D | 1 | 2018 | 3310 | 0.060 |
Why?
|
| Hospitals, Veterans | 1 | 2006 | 395 | 0.060 |
Why?
|
| Mood Disorders | 2 | 2008 | 1129 | 0.060 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2005 | 311 | 0.060 |
Why?
|
| Phentermine | 2 | 2021 | 31 | 0.060 |
Why?
|
| Hospitals, Teaching | 2 | 2014 | 1158 | 0.060 |
Why?
|
| Hematocrit | 3 | 2011 | 625 | 0.060 |
Why?
|
| Pilot Projects | 4 | 2024 | 8731 | 0.060 |
Why?
|
| Aspirin | 2 | 2007 | 3135 | 0.060 |
Why?
|
| Schizophrenia | 2 | 2017 | 6987 | 0.060 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 575 | 0.060 |
Why?
|
| Cross Infection | 1 | 2013 | 1426 | 0.060 |
Why?
|
| Budesonide | 1 | 2024 | 162 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1545 | 0.050 |
Why?
|
| Aerosols | 1 | 2006 | 637 | 0.050 |
Why?
|
| Accidental Falls | 1 | 2011 | 1080 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 1996 | 2412 | 0.050 |
Why?
|
| Medication Errors | 1 | 2009 | 784 | 0.050 |
Why?
|
| Outpatients | 1 | 2011 | 1604 | 0.050 |
Why?
|
| Consensus | 2 | 2023 | 3212 | 0.050 |
Why?
|
| Digoxin | 1 | 2004 | 246 | 0.050 |
Why?
|
| Direct Service Costs | 1 | 2002 | 61 | 0.050 |
Why?
|
| Pandemics | 3 | 2022 | 8753 | 0.050 |
Why?
|
| Dopamine Agonists | 1 | 2005 | 353 | 0.050 |
Why?
|
| Influenza, Human | 1 | 2014 | 1539 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2004 | 1684 | 0.050 |
Why?
|
| Heart Failure, Diastolic | 1 | 2023 | 77 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2013 | 2784 | 0.050 |
Why?
|
| Public Health | 1 | 1996 | 2682 | 0.050 |
Why?
|
| Reference Standards | 2 | 2022 | 1013 | 0.050 |
Why?
|
| Perimenopause | 1 | 2023 | 142 | 0.050 |
Why?
|
| Pyrroles | 1 | 2008 | 1126 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 2257 | 0.050 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2005 | 277 | 0.050 |
Why?
|
| Drug and Narcotic Control | 1 | 2003 | 145 | 0.050 |
Why?
|
| Lipids | 1 | 2012 | 3344 | 0.050 |
Why?
|
| Headache Disorders | 1 | 2004 | 152 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 997 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2005 | 683 | 0.050 |
Why?
|
| Iron | 1 | 2010 | 1814 | 0.050 |
Why?
|
| Comoros | 1 | 2020 | 12 | 0.050 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2024 | 399 | 0.050 |
Why?
|
| Acute Chest Syndrome | 1 | 2020 | 32 | 0.040 |
Why?
|
| Patient Discharge | 3 | 2004 | 3476 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2001 | 164 | 0.040 |
Why?
|
| Reimbursement Mechanisms | 1 | 2006 | 677 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 2544 | 0.040 |
Why?
|
| Inservice Training | 1 | 2003 | 375 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 6856 | 0.040 |
Why?
|
| Nocturia | 1 | 2019 | 18 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2005 | 577 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2004 | 775 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 523 | 0.040 |
Why?
|
| Poverty | 2 | 2012 | 2721 | 0.040 |
Why?
|
| Appetite Depressants | 1 | 2000 | 108 | 0.040 |
Why?
|
| Depression | 3 | 2019 | 8241 | 0.040 |
Why?
|
| Rheumatic Diseases | 1 | 2006 | 662 | 0.040 |
Why?
|
| Taxoids | 1 | 2023 | 668 | 0.040 |
Why?
|
| Arthralgia | 1 | 2023 | 459 | 0.040 |
Why?
|
| Aromatase Inhibitors | 1 | 2023 | 519 | 0.040 |
Why?
|
| Androstadienes | 1 | 2021 | 348 | 0.040 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2019 | 79 | 0.040 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2003 | 497 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2007 | 1161 | 0.040 |
Why?
|
| Adrenergic Antagonists | 1 | 2018 | 26 | 0.040 |
Why?
|
| Clarithromycin | 1 | 2019 | 87 | 0.040 |
Why?
|
| Physician's Role | 1 | 2005 | 926 | 0.040 |
Why?
|
| Animals | 3 | 2022 | 169337 | 0.040 |
Why?
|
| Glutens | 1 | 2001 | 240 | 0.040 |
Why?
|
| Glucagon-Like Peptides | 1 | 2020 | 155 | 0.040 |
Why?
|
| Quinolones | 2 | 2014 | 382 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2023 | 577 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 3236 | 0.040 |
Why?
|
| Peptic Ulcer Perforation | 1 | 2017 | 23 | 0.040 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2020 | 285 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2019 | 485 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2007 | 2258 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 1664 | 0.040 |
Why?
|
| Carbamazepine | 1 | 2018 | 224 | 0.040 |
Why?
|
| Pharmacists | 1 | 2020 | 261 | 0.040 |
Why?
|
| Netherlands | 3 | 2008 | 2274 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 417 | 0.040 |
Why?
|
| Bone Density | 2 | 2012 | 3559 | 0.040 |
Why?
|
| Validation Studies as Topic | 1 | 2017 | 162 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2011 | 3981 | 0.040 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2022 | 1114 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2023 | 12456 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 7453 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2022 | 1026 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2004 | 1838 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 2010 | 1629 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2004 | 2728 | 0.030 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 1996 | 43 | 0.030 |
Why?
|
| Acute Disease | 1 | 2007 | 7242 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2002 | 1142 | 0.030 |
Why?
|
| Health Care Surveys | 2 | 2019 | 2437 | 0.030 |
Why?
|
| Hospitals, General | 1 | 2001 | 807 | 0.030 |
Why?
|
| Health Care Costs | 2 | 2024 | 3267 | 0.030 |
Why?
|
| Penicillamine | 1 | 2016 | 60 | 0.030 |
Why?
|
| Delirium | 1 | 2008 | 1695 | 0.030 |
Why?
|
| Health Care Reform | 2 | 2012 | 1262 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2017 | 223 | 0.030 |
Why?
|
| Tetrazoles | 1 | 2022 | 923 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 857 | 0.030 |
Why?
|
| Sulfasalazine | 1 | 2016 | 85 | 0.030 |
Why?
|
| Crystallization | 1 | 1997 | 521 | 0.030 |
Why?
|
| Candidiasis | 1 | 2018 | 367 | 0.030 |
Why?
|
| Motor Activity | 1 | 2006 | 2720 | 0.030 |
Why?
|
| Italy | 1 | 2018 | 854 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2022 | 2663 | 0.030 |
Why?
|
| Denmark | 1 | 2018 | 779 | 0.030 |
Why?
|
| Cholelithiasis | 1 | 1997 | 408 | 0.030 |
Why?
|
| Physician-Patient Relations | 2 | 2005 | 3267 | 0.030 |
Why?
|
| Uncertainty | 1 | 2020 | 759 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2018 | 594 | 0.030 |
Why?
|
| Minocycline | 1 | 2016 | 170 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1997 | 236 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2007 | 2400 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2009 | 3312 | 0.030 |
Why?
|
| Injections | 1 | 2017 | 840 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2005 | 2103 | 0.030 |
Why?
|
| Parathyroid Glands | 1 | 1996 | 522 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 969 | 0.030 |
Why?
|
| Natural Language Processing | 1 | 2023 | 1202 | 0.030 |
Why?
|
| Cholesterol | 2 | 2007 | 2912 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2020 | 1575 | 0.030 |
Why?
|
| Infant, Newborn | 4 | 2014 | 26411 | 0.030 |
Why?
|
| Formularies as Topic | 2 | 2004 | 94 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 2226 | 0.030 |
Why?
|
| Organizations | 1 | 2014 | 172 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2024 | 1309 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2020 | 838 | 0.030 |
Why?
|
| Isoxazoles | 1 | 2014 | 233 | 0.030 |
Why?
|
| Gastric Acidity Determination | 1 | 2012 | 56 | 0.030 |
Why?
|
| Celiac Disease | 1 | 2001 | 820 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2019 | 723 | 0.030 |
Why?
|
| Switzerland | 1 | 2013 | 323 | 0.030 |
Why?
|
| Phenotype | 2 | 2022 | 16721 | 0.030 |
Why?
|
| Hospitals, Rural | 1 | 2014 | 176 | 0.030 |
Why?
|
| Cognition | 1 | 2010 | 7075 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2001 | 1364 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2014 | 500 | 0.020 |
Why?
|
| alpha-Glucosidases | 1 | 2012 | 46 | 0.020 |
Why?
|
| Hyperuricemia | 1 | 2015 | 223 | 0.020 |
Why?
|
| Internationality | 1 | 2017 | 1008 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 1486 | 0.020 |
Why?
|
| Adiposity | 1 | 2021 | 1895 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 3731 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2001 | 1215 | 0.020 |
Why?
|
| Parkinson Disease | 1 | 2005 | 2895 | 0.020 |
Why?
|
| Liver | 1 | 2007 | 7574 | 0.020 |
Why?
|
| Specialization | 1 | 1996 | 781 | 0.020 |
Why?
|
| Electronic Prescribing | 1 | 2011 | 115 | 0.020 |
Why?
|
| Tablets | 1 | 2011 | 149 | 0.020 |
Why?
|
| Markov Chains | 2 | 2005 | 977 | 0.020 |
Why?
|
| Rupture | 1 | 2012 | 444 | 0.020 |
Why?
|
| Calcinosis | 1 | 2019 | 1481 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2016 | 2226 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2018 | 1187 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2022 | 9562 | 0.020 |
Why?
|
| Retreatment | 1 | 2011 | 600 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2010 | 301 | 0.020 |
Why?
|
| Clinical Audit | 1 | 2009 | 29 | 0.020 |
Why?
|
| Achilles Tendon | 1 | 2012 | 181 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2012 | 505 | 0.020 |
Why?
|
| Pregnancy | 2 | 2023 | 30200 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2000 | 2598 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1482 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2721 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 2022 | 3910 | 0.020 |
Why?
|
| Nonprescription Drugs | 1 | 2010 | 119 | 0.020 |
Why?
|
| Minnesota | 1 | 2009 | 338 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2000 | 1597 | 0.020 |
Why?
|
| Coronary Artery Disease | 2 | 2019 | 6567 | 0.020 |
Why?
|
| Observation | 1 | 2010 | 311 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 1317 | 0.020 |
Why?
|
| Life Style | 1 | 2019 | 3929 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 3044 | 0.020 |
Why?
|
| Heparin | 1 | 2015 | 1636 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 2488 | 0.020 |
Why?
|
| Memory | 1 | 2016 | 2210 | 0.020 |
Why?
|
| Negotiating | 1 | 2008 | 152 | 0.020 |
Why?
|
| Models, Econometric | 1 | 2007 | 215 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2008 | 411 | 0.020 |
Why?
|
| Prejudice | 1 | 2010 | 574 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 1996 | 1765 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 1410 | 0.020 |
Why?
|
| Diuretics | 1 | 2009 | 612 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 2972 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5422 | 0.020 |
Why?
|
| Laparoscopy | 1 | 1996 | 2056 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 985 | 0.010 |
Why?
|
| Antiparkinson Agents | 1 | 2005 | 184 | 0.010 |
Why?
|
| Ohio | 1 | 2005 | 328 | 0.010 |
Why?
|
| Hospital Records | 1 | 2004 | 93 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 2587 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2004 | 202 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 18362 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2008 | 940 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 318 | 0.010 |
Why?
|
| Medical Audit | 1 | 2004 | 454 | 0.010 |
Why?
|
| Scotland | 1 | 2002 | 142 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2019 | 4713 | 0.010 |
Why?
|
| Ireland | 1 | 2002 | 170 | 0.010 |
Why?
|
| Life Tables | 1 | 2002 | 368 | 0.010 |
Why?
|
| Software Design | 1 | 2002 | 172 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2004 | 685 | 0.010 |
Why?
|
| Curriculum | 1 | 1996 | 3776 | 0.010 |
Why?
|
| Mammography | 1 | 2012 | 2434 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 599 | 0.010 |
Why?
|
| Cardiology | 1 | 2012 | 1701 | 0.010 |
Why?
|
| Health Planning | 1 | 2002 | 232 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2005 | 1762 | 0.010 |
Why?
|
| Glaucoma | 1 | 2011 | 1194 | 0.010 |
Why?
|
| Troponin | 1 | 2004 | 534 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2010 | 1959 | 0.010 |
Why?
|
| Infant Food | 1 | 2001 | 139 | 0.010 |
Why?
|
| Emergencies | 1 | 2007 | 1219 | 0.010 |
Why?
|
| Fenfluramine | 1 | 2000 | 58 | 0.010 |
Why?
|
| Exercise | 1 | 2016 | 5946 | 0.010 |
Why?
|
| Creatinine | 1 | 2005 | 1915 | 0.010 |
Why?
|
| Amphetamines | 1 | 2000 | 143 | 0.010 |
Why?
|
| Range of Motion, Articular | 1 | 2005 | 1599 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2005 | 1249 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2005 | 975 | 0.010 |
Why?
|
| Aging | 1 | 2016 | 8764 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2005 | 2226 | 0.010 |
Why?
|
| Drug Industry | 1 | 2003 | 793 | 0.010 |
Why?
|
| Bile | 1 | 1997 | 299 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 82017 | 0.010 |
Why?
|
| Electron Transport | 1 | 1996 | 211 | 0.010 |
Why?
|
| Radiography | 1 | 2006 | 6993 | 0.010 |
Why?
|
| Age of Onset | 1 | 2001 | 3345 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1996 | 1153 | 0.010 |
Why?
|
| Psychometrics | 1 | 2002 | 3069 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 1905 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2008 | 8541 | 0.010 |
Why?
|
| Point Mutation | 1 | 1996 | 1594 | 0.010 |
Why?
|
| DNA, Mitochondrial | 1 | 1996 | 871 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 7880 | 0.000 |
Why?
|
| Nurses | 1 | 1997 | 2494 | 0.000 |
Why?
|
| Base Sequence | 1 | 1996 | 12422 | 0.000 |
Why?
|
| Quality of Life | 1 | 2005 | 13503 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 17626 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1996 | 11120 | 0.000 |
Why?
|